273 related articles for article (PubMed ID: 30142881)
1. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30142881
[TBL] [Abstract][Full Text] [Related]
2. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms.
D'Amore C; Moro E; Borgo C; Itami K; Hirota T; Pinna LA; Salvi M
Biochim Biophys Acta Mol Cell Res; 2020 Nov; 1867(11):118807. PubMed ID: 32745724
[TBL] [Abstract][Full Text] [Related]
3. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
[TBL] [Abstract][Full Text] [Related]
4. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
[TBL] [Abstract][Full Text] [Related]
5. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
6. The Casein Kinase 2 Inhibitor CX-4945 Promotes Cholangiocarcinoma Cell Death Through PLK1.
Lee DS; Lee S; Kim C; Kim D; Kim KP; Yoo C
Anticancer Res; 2022 Jul; 42(7):3435-3443. PubMed ID: 35790285
[TBL] [Abstract][Full Text] [Related]
7. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein kinase CK2 in the treatment of cholangiocarcinoma.
Jayaraman PS; Gaston K
Explor Target Antitumor Ther; 2021; 2(5):434-447. PubMed ID: 36045705
[TBL] [Abstract][Full Text] [Related]
9. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
10. Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism.
Lertsuwan J; Lertsuwan K; Sawasdichai A; Tasnawijitwong N; Lee KY; Kitchen P; Afford S; Gaston K; Jayaraman PS; Satayavivad J
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612322
[TBL] [Abstract][Full Text] [Related]
11. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
12. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC
PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409
[TBL] [Abstract][Full Text] [Related]
13. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
15. Casein kinase 2 phosphorylates and induces the SALL2 tumor suppressor degradation in colon cancer cells.
Hermosilla VE; Gyenis L; Rabalski AJ; Armijo ME; Sepúlveda P; Duprat F; Benítez-Riquelme D; Fuentes-Villalobos F; Quiroz A; Hepp MI; Farkas C; Mastel M; González-Chavarría I; Jackstadt R; Litchfield DW; Castro AF; Pincheira R
Cell Death Dis; 2024 Mar; 15(3):223. PubMed ID: 38493149
[TBL] [Abstract][Full Text] [Related]
16. Regulation of TMEM16A by CK2 and Its Role in Cellular Proliferation.
Pinto MC; Schreiber R; Lerias J; Ousingsawat J; Duarte A; Amaral M; Kunzelmann K
Cells; 2020 May; 9(5):. PubMed ID: 32380794
[TBL] [Abstract][Full Text] [Related]
17. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY
Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of casein kinase 2 prevents growth of human osteosarcoma.
Takahashi K; Setoguchi T; Tsuru A; Saitoh Y; Nagano S; Ishidou Y; Maeda S; Furukawa T; Komiya S
Oncol Rep; 2017 Feb; 37(2):1141-1147. PubMed ID: 27959425
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.
Pizzi M; Piazza F; Agostinelli C; Fuligni F; Benvenuti P; Mandato E; Casellato A; Rugge M; Semenzato G; Pileri SA
Oncotarget; 2015 Mar; 6(9):6544-52. PubMed ID: 25788269
[TBL] [Abstract][Full Text] [Related]
20. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
